1cBio is a biopharma company developing precision medicines targeting defined mechanisms of action in cancer therapies, including an oral ENPP1 inhibitor for hypophosphatasia and a selective PARP1 inhibitor for HR deficient and proficient tumors. Their approach addresses the challenge of acquired and intrinsic resistance in cancer treatment by leveraging medicinal chemistry and translational sciences in collaboration with clinical and basic science partners.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers develop resistance to existing therapies through mechanisms such as ENPP1 overexpression or PARP inhibitor resistance, limiting treatment options and leading to disease progression. Current PARP inhibitors often lack selectivity, causing off-target effects and limiting their efficacy in treating tumors with homologous recombination (HR) proficiency.
Solution
1cBio is developing precision medicines to overcome resistance mechanisms in cancer. Their lead program is an oral ENPP1 inhibitor designed to address hypophosphatasia and enhance the efficacy of other cancer therapies. They are also developing a selective PARP1 inhibitor that targets both HR deficient and HR proficient tumors, aiming to improve treatment outcomes in breast, prostate, and pancreatic cancers while minimizing off-target effects. 1cBio leverages medicinal chemistry and translational sciences to create molecules that preemptively counter mechanisms for acquired or intrinsic resistance.
Target Audience
The primary target audience includes patients with cancers that have developed resistance to existing therapies, as well as clinicians seeking more effective and targeted treatment options.
Features
- Oral ENPP1 inhibitor designed to overcome resistance mechanisms in cancer therapies.
- Selective PARP1 inhibitor targeting both HR deficient and HR proficient tumors.
- Focus on defined mechanisms of action validated in clinical practice, clinical trials, or preclinical models.
- Programs designed to preemptively counter mechanisms for acquired or intrinsic resistance.
- Utilizes medicinal chemistry and translational sciences.
- Discovery platform is rapidly scalable and easily tailored to suit current and future needs.